Neuroendocrine Tumor Patients Whose Lutetium Therapy Stopped Working Saw Slower Progression on Actinium-Based RYZ101 in Phase 3 Trial Medical Daily 7d
Bristol-Myers Squibb Announces Positive Topline Data From RYZ101 Study, Stock Up In Pre-Market RTT News 13:47 Mon, 12 Oct
Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 action-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with Gep-NETs Business Wire (Press Release) 11:57 Mon, 12 Oct
Bristol Myers Squibb vs. Eli Lilly: How long can zepbound and mounjaro keep juicing Revenue results? The Motley Fool 19h Eli Lilly Mounjaro Pharma
BMS gains two pivotal trial wins in lung disease and rare cancer Clinical Trials Arena 09:05 Tue, 13 Oct All sources
Neuroendocrine tumor patients whose lutetium therapy stopped working saw slower progression on actinium-based RYZ101 in Phase 3 trial Medical Daily 7d RYZ101 Radiation Cancer Treatment All sources
